Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
$0.00
$0.00
$0.00
$6K1.6183,499 shsN/A
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
$1.03
+59.4%
$0.37
$0.55
$1,200.00
$4.32MN/A732,281 shs51.66 million shs
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
$0.00
$0.00
$0.00
$0.01
$13K-0.292,056 shsN/A
Smart for Life, Inc. stock logo
SMFL
Smart for Life
$0.04
+1,496.0%
$0.00
$0.00
$7.68
$283K1.634,184 shs2,869 shs
10 Stocks Set to Soar in Spring 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
0.00%0.00%0.00%0.00%+150.00%
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
+58.46%+18,974.07%+228.23%+16.87%+102,999,900.00%
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
0.00%0.00%0.00%0.00%-85.71%
Smart for Life, Inc. stock logo
SMFL
Smart for Life
+1,496.00%+19,850.00%+3,890.00%+398.75%-98.81%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
N/AN/AN/AN/AN/AN/AN/AN/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
N/AN/AN/AN/AN/AN/AN/AN/A
Smart for Life, Inc. stock logo
SMFL
Smart for Life
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
0.00
N/AN/AN/A
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
0.00
N/AN/AN/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
0.00
N/AN/AN/A
Smart for Life, Inc. stock logo
SMFL
Smart for Life
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
$1.91M0.00N/AN/A$0.47 per share0.00
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
N/AN/AN/AN/AN/AN/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
N/AN/AN/AN/AN/AN/A
Smart for Life, Inc. stock logo
SMFL
Smart for Life
$11.11M0.03N/AN/A($17.10) per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
-$33.20M-$0.61N/AN/AN/AN/A-182.88%-62.76%N/A
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
N/AN/A0.00N/AN/AN/AN/AN/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
-$11.61MN/A0.00N/AN/AN/AN/AN/A
Smart for Life, Inc. stock logo
SMFL
Smart for Life
-$22.68MN/A0.00N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
N/AN/AN/AN/AN/A
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
N/AN/AN/AN/AN/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
N/AN/AN/AN/AN/A
Smart for Life, Inc. stock logo
SMFL
Smart for Life
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
0.24
1.35
1.35
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
N/AN/AN/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
N/AN/AN/A
Smart for Life, Inc. stock logo
SMFL
Smart for Life
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
0.64%
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
N/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
N/A
Smart for Life, Inc. stock logo
SMFL
Smart for Life
28.39%

Insider Ownership

CompanyInsider Ownership
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
1.61%
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
N/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
5.10%
Smart for Life, Inc. stock logo
SMFL
Smart for Life
31.71%
CompanyEmployeesShares OutstandingFree FloatOptionable
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
7058.73 million57.79 millionNot Optionable
Polyrizon Ltd. stock logo
PLRZ
Polyrizon
N/A4.19 millionN/AN/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
942.08 million39.94 millionNot Optionable
Smart for Life, Inc. stock logo
SMFL
Smart for Life
1107.09 million4.84 millionNot Optionable

Recent News About These Companies

Smart for Life Inc. (SMFL) Analyst Research
SMART High School Common App Workshop
Smart supramolecular assemblies
HRT Financial LP Acquires New Stake in Smart for Life Inc

New MarketBeat Followers Over Time

Media Sentiment Over Time

Genocea Biosciences stock logo

Genocea Biosciences NASDAQ:GNCA

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.

Polyrizon stock logo

Polyrizon NASDAQ:PLRZ

$1.03 +0.38 (+59.44%)
As of 05/28/2025 04:00 PM Eastern

Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.

Scopus BioPharma stock logo

Scopus BioPharma NASDAQ:SCPS

$0.0003 0.00 (0.00%)
As of 05/27/2025

Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses. The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein. Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.

Smart for Life stock logo

Smart for Life NASDAQ:SMFL

$0.04 +0.04 (+1,496.00%)
As of 05/28/2025 03:58 PM Eastern

Smart for Life, Inc. acquires, develops, manufactures, operates, markets, and sells nutraceutical and related products in the United States and internationally. It offers natural health and wellness meal replacement products, including nutrition bars, cookies, soups and shakes, vitamins, and supplements under the Smart for Life brand; dietary supplements; and nutritional products, including whey protein isolate powder, tablet supplements for joint health, nitric oxide, post workout blends, Omega-3 supplements, and pre-workout supplements under the Sports Illustrated Nutrition brand for athletes and active lifestyle consumers. The company also provides various nutritional products, including antioxidant rich supplements, plant-based proteins, alkalizing nutrients, and weight management products. It sells its products through online market platforms. The company was formerly known as Bonne Santé Group, Inc. and changed its name to Smart for Life, Inc. in August 2021. Smart for Life, Inc. was founded in 2002 and is based in Boca Raton, Florida.